From the Editor's Desk. [0.03%]
主编说
Patrizia Burra,Frank Tacke,Vlad Ratziu et al.
Patrizia Burra et al.
Mariana M Ramírez-Mejía,Mohammed Eslam,Nahum Méndez-Sánchez
Mariana M Ramírez-Mejía
Ciro Celsa,Giuseppe Cabibbo,David James Pinato
Ciro Celsa
Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis [0.03%]
EASL管理算法在肝硬化急性肾损伤中的前瞻性验证研究
Ann Thu Ma,Cristina Solé,Adrià Juanola et al.
Ann Thu Ma et al.
Background & aims: The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm for the management of AKI, but this has never been validated. We aimed to prospectively...
One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands [0.03%]
荷兰重症监护室收治的ACLF患者出院后一年内的移植前生存率研究
Jubi de Haan,Fabian Termorshuizen,Nicolette de Keizer et al.
Jubi de Haan et al.
Background & aims: Patients with acute decompensation of cirrhosis or acute-on-chronic liver failure (ACLF) often require intensive care unit (ICU) admission for organ support. Existing research, mostly from specialized l...
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta [0.03%]
Baveno VII标准及其他非侵入性诊断算法在乙型肝炎中对临床显著门脉高压的验证
Mathias Jachs,Lisa Sandmann,Lukas Hartl et al.
Mathias Jachs et al.
Background & aims: Non-invasive tests (NITs) for clinically significant portal hypertension (CSPH) require validation in patients with hepatitis D virus (HDV)-related compensated advanced chronic liver disease (cACLD). Th...
Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study [0.03%]
立体定向消融放疗在寡转移性肝细胞癌患者中的疗效：一项二期研究
Seo Hee Choi,Byung Min Lee,Jina Kim et al.
Seo Hee Choi et al.
Background & aims: Stereotactic ablative radiotherapy (SABR) can extend survival and offers the potential for cure in some patients with oligometastatic disease (OMD). However, limited evidence exists regarding its use in...
Clinical Trial
Journal of hepatology. 2024 Jul;81(1):84-92. DOI:10.1016/j.jhep.2024.03.003 2024
Shivaram Prasad Singh,Prajna Anirvan
Shivaram Prasad Singh
Reply to: "Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies" [0.03%]
对《超灵敏HBsAg检测预测HBsAg血清反转结局：新疗法和现有疗法的考量》的回复
Marc G Ghany,Maria Buti,Pietro Lampertico et al.
Marc G Ghany et al.